<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-160212" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Angiotensin Receptor Blockers and HCTZ Combination Drugs</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sagar</surname>
            <given-names>Sheeba</given-names>
          </name>
          <aff>Christian Medical College, Ludhiana</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold> Sheeba Sagar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-160212.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Hypertension&#x000a0;contributes significantly to cardiovascular and all-cause mortality rates. Between 2017-2018, the prevalence&#x000a0;of hypertension in adults in the U.S. was 45%, with&#x000a0;a significant fraction of these patients belonging to&#x000a0;older age groups.<xref ref-type="bibr" rid="article-160212.r1">[1]</xref>&#x000a0;The global burden of systemic hypertension continues to rise, and it is estimated that 1.6 billion people will be affected by 2025.<xref ref-type="bibr" rid="article-160212.r2">[2]</xref>&#x000a0;A significant number of patients with hypertension require more than 2 antihypertensive agents to achieve adequate blood pressure control. There is a significant cardiovascular benefit when drugs from&#x000a0;different medication types are&#x000a0;co-administered&#x000a0;compared to increasing monotherapy doses.<xref ref-type="bibr" rid="article-160212.r3">[3]</xref> Considering the crucial role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of hypertension, angiotensin receptor blockers (ARB) are first-line drugs&#x000a0;prescribed to treat hypertension. Adding a thiazide diuretic (eg, hydrochlorothiazide (HCTZ)) to the regimen improves&#x000a0;blood pressure control through synergistic action.&#x000a0;</p>
        <p>Despite therapeutic advances, blood pressure control remains at&#x000a0;unacceptable&#x000a0;levels worldwide. To address this issue, current guidelines recommend the widespread use of combination antihypertensive therapy,&#x000a0;specifically regimens involving fixed-dose single-pill medications. Combination antihypertensive therapy in fixed-dose combination formulations has demonstrated significant and sustained reductions in systolic and diastolic blood pressure. This approach&#x000a0;is also associated with improved patient adherence, tolerability, and medication persistence, ultimately leading to&#x000a0;improved blood pressure control and&#x000a0;a reduced risk of major cardiovascular events and hospitalizations.<xref ref-type="bibr" rid="article-160212.r4">[4]</xref><bold>&#x000a0;</bold></p>
        <p>Combining an angiotensin receptor blocker and hydrochlorothiazide (ARB-HCTZ) is the&#x000a0;recommended initial treatment for patients requiring multiple medications to manage their blood pressure, as well as an additional therapy for patients with uncontrolled blood pressure on monotherapy. The maximum antihypertensive effect is typically observed&#x000a0;4 weeks after treatment initiation, with minimal to no occurrence of orthostatic hypotension.<xref ref-type="bibr" rid="article-160212.r5">[5]</xref> The ARB-HCTZ combination effectively&#x000a0;reduces proteinuria by inhibiting the accelerated activity of RAAS in patients with diabetic nephropathy, an off-label indication for using this&#x000a0;medication.<xref ref-type="bibr" rid="article-160212.r6">[6]</xref><xref ref-type="bibr" rid="article-160212.r7">[7]</xref>&#x000a0;The combination should be discontinued&#x000a0;for patients who are&#x000a0;pregnant, hypotensive, or have abnormal serum potassium levels.&#x000a0;</p>
        <p>According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines, thiazide diuretics, calcium channel blockers (CCBs), and angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are recommended as first-line agents for treating hypertension.<xref ref-type="bibr" rid="article-160212.r8">[8]</xref>&#x000a0;Single-pill combination (SPC) antihypertensive therapies, also referred to as fixed-dose combinations (FDC), are extensively utilized for the management of elevated blood pressure. This is&#x000a0;thought&#x000a0;to be due to the&#x000a0;multiple medications needed to&#x000a0;achieve target blood pressure levels in at least 75% of patients with hypertension.<xref ref-type="bibr" rid="article-160212.r9">[9]</xref>&#x000a0;</p>
        <p>According to the International Society of Hypertension (ISH) guidelines for the management of hypertension, annual screening for hypertension is recommended for all adults whenever possible. Lifestyle modifications&#x000a0;include reducing salt intake, increasing vegetable and fruit consumption&#x000a0;(potassium sources),&#x000a0;appropriate weight management, and limiting alcohol consumption. ISH endorses the use of single-pill combinations to reduce pill burden.<xref ref-type="bibr" rid="article-160212.r9">[9]</xref><xref ref-type="bibr" rid="article-160212.r10">[10]</xref>&#x000a0;</p>
        <p>The 2023 European Society of Hypertension (ESH) guidelines recommend initiating therapy with a 2-drug combination for&#x000a0;most patients with hypertension. The&#x000a0;standard therapy&#x000a0;typically includes a renin-angiotensin system (RAS) blocker (ACE inhibitor or ARB) combined with a CCB or a thiazide (or thiazide-like) diuretic. Antihypertensive medications, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and thiazide/thiazide-like diuretics, can prevent coronary artery disease (CAD).<xref ref-type="bibr" rid="article-160212.r11">[11]</xref>&#x000a0;</p>
        <p>In a multinational retrospective cohort study comparing the real-world effectiveness and safety of ACE inhibitors versus ARBs as first-line treatment for hypertension, no statistically significant differences were observed between ACEIs and ARBs in primary outcomes like&#x000a0;heart failure, acute myocardial infarction, stroke, or composite cardiovascular events. However, ARBs demonstrated a lower risk of secondary outcomes such as cough, angioedema, pancreatitis, and gastrointestinal bleeding. These findings suggest that ARBs may be preferable&#x000a0;over ACE inhibitors due to their comparable effectiveness and potentially better safety profile in initiating treatment for hypertension.<xref ref-type="bibr" rid="article-160212.r12">[12]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>All fixed-dose&#x000a0;ARB-HCTZ combinations are FDA-approved&#x000a0;to treat hypertension. Additionally, losartan-hydrochlorothiazide is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.<xref ref-type="bibr" rid="article-160212.r13">[13]</xref>&#x000a0;This protective effect may not extend to all patients.<xref ref-type="bibr" rid="article-160212.r14">[14]</xref>&#x000a0;However, ARBs are beneficial for patients with comorbidities such as diabetic nephropathy or&#x000a0;heart failure with reduced ejection fraction (HFrEF).<xref ref-type="bibr" rid="article-160212.r15">[15]</xref>&#x000a0;A list of single-pill combinations is provided below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Valsartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Olmesartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Telmisartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Irbesartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Candesartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Losartan and hydrochlorothiazide</p>
          </list-item>
          <list-item>
            <p>Eprosartan and hydrochlorothiazide</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>According to the AHA/ACC 2022 guidelines for heart failure, thiazide diuretics like hydrochlorothiazide may be considered in patients with hypertension, heart failure, and mild fluid retention. Inhibition of the renin-angiotensin system with angiotensin receptor neprilysin inhibitors (ARNI), ACE inhibitors, or ARB improves outcomes for patients with HFrEF.<xref ref-type="bibr" rid="article-160212.r15">[15]</xref>&#x000a0;According to the American Diabetes Association guidelines, combination ARBs/ACE inhibitors are first-line agents&#x000a0;to treat&#x000a0;patients with hypertension and diabetes, GFR &#x0003c;60 mL/min/1.73 m<sup>2</sup>,&#x000a0;or a urinary albumin-to-creatinine ratio &#x02265;300 mg albumin:g creatinine because of their established benefits for preventing CKD progression.<xref ref-type="bibr" rid="article-160212.r16">[16]</xref>&#x000a0;However, the potential for dysglycemia with hydrochlorothiazide administration should be taken into consideration for&#x000a0;patients with diabetes.<xref ref-type="bibr" rid="article-160212.r17">[17]</xref></p>
      </sec>
      <sec id="article-160212.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Excessive and inappropriate activation of the&#x000a0;renin-angiotensin-aldosterone system&#x000a0;(RAAS)&#x000a0;is a critical&#x000a0;component&#x000a0;of hypertension development. Various&#x000a0;elements&#x000a0;of RAAS are&#x000a0;targets&#x000a0;for&#x000a0;blood pressure therapy. Prorenin (a precursor of renin) is stored in juxtaglomerular cells (JG cells) within the renal afferent arterioles. Prorenin is enzymatically cleaved to form renin under specific stimuli such as renal hypoperfusion, reduced delivery of sodium and chloride to the distal convoluted tubule (DCT),&#x000a0;or increased sympathetic flow through the &#x003b2;-1 adrenergic receptors.<xref ref-type="bibr" rid="article-160212.r18">[18]</xref></p>
        <p>Renin is produced by the liver and initiates the conversion of angiotensinogen into angiotensin I. In the lungs, angiotensin-converting enzyme (ACE) removes&#x000a0;2 amino acids from the C terminal of angiotensin I to form angiotensin II, which&#x000a0;regulates blood volume through the AT1 receptor. By inhibiting the binding of angiotensin II to AT1 receptors in the kidneys and adrenal glands, angiotensin receptor blockers impede vasoconstriction and the involvement of aldosterone in the progression of cardiovascular diseases.<xref ref-type="bibr" rid="article-160212.r19">[19]</xref><xref ref-type="bibr" rid="article-160212.r20">[20]</xref>&#x000a0;HCTZ is a diuretic agent that acts on the DCTs. Sodium is absorbed in the DCTs and transported to the basolateral aspect of the interstitium through the activity of a sodium-potassium ATPase pump. This process establishes a concentration gradient across the epithelial cells and the DCTs, facilitating water reabsorption. HCTZ hinders sodium and chloride transport by targeting the sodium-chloride symporter, also known as Solute Carrier Family 12 Member 3 (SLC12A3). Through this interruption, HCTZ reduces the concentration difference between the DCT and epithelial cells,&#x000a0;reducing water reabsorption&#x000a0;and increasing diuresis.<xref ref-type="bibr" rid="article-160212.r8">[8]</xref><xref ref-type="bibr" rid="article-160212.r21">[21]</xref></p>
        <p>ARBs selectively target the AT1 receptor, reducing vasoconstriction and aldosterone secretion induced by angiotensin II. Meanwhile, HCTZ inhibits sodium and water reabsorption in the proximal DCT, promoting diuresis. These mechanisms synergistically&#x000a0;reduce blood pressure by&#x000a0;mediating&#x000a0;vascular tone and fluid volume. This approach optimizes therapeutic efficacy while mitigating the risk of electrolyte imbalances and other adverse effects associated with higher doses of individual agents. A meta-analysis compared ARB-HCTZ therapy to ARB alone in patients with uncontrolled hypertension. Results from 16 RCTs (12,055 participants) indicated that ARB-HCTZ achieved significantly improved systolic and diastolic blood pressures than ARB alone. The combination also increased the likelihood of reaching target blood pressure goals. ARB-HCTZ&#x000a0;is associated with&#x000a0;rates of adverse events similar to ARB alone.<xref ref-type="bibr" rid="article-160212.r22">[22]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>Valsartan is rapidly absorbed following oral&#x000a0;administration&#x000a0;and reaches peak plasma concentration after 1 to 2 hours.<xref ref-type="bibr" rid="article-160212.r23">[23]</xref>&#x000a0;Olmesartan is esterified with medoxomil to increase its bioavailability, allowing it to reach peak plasma concentration within 1 to 3 hours.<xref ref-type="bibr" rid="article-160212.r24">[24]</xref>&#x000a0;According to FDA-approved product labeling, telmisartan (20 to 160 mg) follows non-linear pharmacokinetics,&#x000a0;and its dose-dependent bioavailability ranges from 42% to 58%. The bioavailability of irbesartan is 60% to 80% after a dose. Food intake does not affect its bioavailability. The prodrug candesartan cilexetil is rapidly activated after absorption from the gastrointestinal tract, and its bioavailability is 40% after an oral dose.<xref ref-type="bibr" rid="article-160212.r25">[25]</xref>&#x000a0;The bioavailability of losartan is 33%, and concurrent food intake reduces its absorption.<xref ref-type="bibr" rid="article-160212.r26">[26]</xref>&#x000a0;The bioavailability of eprosartan after an oral dose of 300 mg is 13%. The bioavailability of HCTZ ranges from 65% to 75%. However, this&#x000a0;availability is reduced&#x000a0;by 10% when HCTZ is consumed with a meal.<xref ref-type="bibr" rid="article-160212.r27">[27]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>Valsartan and olmesartan bind strongly to plasma proteins, primarily albumin, which significantly reduces their volume of distribution. The volume of distribution for both drugs is 17 L, implying these medications are not distributed extensively throughout the body. Angiotensin receptor blockers such as&#x000a0;telmisartan are highly bound to plasma proteins (&#x0003e;99.5%) regardless&#x000a0;of dose amount. Telmisartan's distribution volume is 500 L.<xref ref-type="bibr" rid="article-160212.r28">[28]</xref>&#x000a0;Irbesartan is 90% bound to&#x000a0;plasma proteins (primarily albumin and &#x003b1;-1-acid glycoprotein), and its volume of distribution ranges from 53 to 93 L. Candesartan is highly bound to plasma proteins and has been shown to cross the blood-brain barrier in animal models; its volume of distribution is 0.13 L/kg. Losartan is 99.7% bound to plasma proteins,&#x000a0;giving it poor&#x000a0;tissue distribution.<xref ref-type="bibr" rid="article-160212.r26">[26]</xref>&#x000a0;Eprosartan at any concentration binds strongly&#x000a0;to plasma proteins. HCTZ is 40% to 68% bound to albumin in the serum and extensively distributed throughout the body.<xref ref-type="bibr" rid="article-160212.r29">[29]</xref></p>
        <p><bold>Metabolism:&#x000a0;</bold>Candesartan cilexetil, olmesartan medoxomil, and azilsartan medoxomil are prodrugs requiring metabolic activation in the GIT and liver to form their active counterparts. In contrast, eprosartan, irbesartan, telmisartan, and valsartan are&#x000a0;active immediately after administration.<xref ref-type="bibr" rid="article-160212.r30">[30]</xref><bold>&#x000a0;</bold>Valsartan undergoes minimal metabolism.<xref ref-type="bibr" rid="article-160212.r23">[23]</xref>&#x000a0;Olmesartan medoxomil is activated into its pharmacologically active form through ester hydrolysis in the gastrointestinal tract; active olmesartan undergoes negligible metabolism.<xref ref-type="bibr" rid="article-160212.r31">[31]</xref>&#x000a0;Telmisartan is minimally metabolized through conjugation into the pharmacologically inactive compound acyl-glucuronide without P450 isoenzymes.<xref ref-type="bibr" rid="article-160212.r28">[28]</xref>&#x000a0;Irbesartan is&#x000a0;primarily&#x000a0;metabolized in the liver through glucuronidation and oxidation by CYP2C9. Candesartan cilexetil undergoes ester hydrolysis to form the pharmacologically active candesartan, which is&#x000a0;not mainly metabolized in the body. However, &#x0003c;20% of the drug undergoes hepatic metabolism through O-deethylation. The maximum amount of candesartan is excreted unchanged in stools. Losartan undergoes a metabolic transformation into an aldehyde intermediate, producing active metabolites.<xref ref-type="bibr" rid="article-160212.r26">[26]</xref>&#x000a0;Eprosartan is not metabolized in the body. HCTZ is also not metabolized in the body and is excreted unchanged in the urine.</p>
        <p><bold>Elimination:</bold>&#x000a0;Valsartan&#x000a0;demonstrates bi-exponential decay kinetics, has a half-life of 6 hours, and is excreted almost unchanged in the feces.<xref ref-type="bibr" rid="article-160212.r23">[23]</xref><xref ref-type="bibr" rid="article-160212.r32">[32]</xref>&#x000a0;The steady-state concentration of valsartan is achieved after&#x000a0;7 days&#x000a0;of&#x000a0;twice-daily dosing.<xref ref-type="bibr" rid="article-160212.r33">[33]</xref>&#x000a0;Olmesartan has a half-life of 10 to 15 hours, takes 3 to 5 days to attain steady-state concentration (once-daily dosing regimen), and 90% of the dose is excreted in feces,&#x000a0;with the remainder excreted in the urine.<xref ref-type="bibr" rid="article-160212.r24">[24]</xref>&#x000a0;Telmisartan is widely regarded as the longest-acting ARB, featuring a mean half-life of 24 hours, which conveniently allows for once-daily dosing.<xref ref-type="bibr" rid="article-160212.r30">[30]</xref>&#x000a0;This drug&#x000a0;demonstrates bi-exponential decay kinetics, has a half-life of 24 hours, and takes 7 daily doses to achieve a steady state.<xref ref-type="bibr" rid="article-160212.r34">[34]</xref>&#x000a0;Irbesartan has a half-life&#x000a0;of 11 to 15 hours, achieves steady-state concentration in 3 days, and 80% of the dose is excreted in feces,&#x000a0;with the remaining excreted in urine. Candesartan reaches its peak concentration in 3 to 4 hours, and its half-life is 9 hours. The active metabolite of losartan has a half-life of 6 to 8 hours. Eprosartan's terminal half-life is 5 to 9 hours.&#x000a0;The other ARBs are also eliminated primarily through feces. Hydrochlorothiazide peaks 4 hours after administration and remains effective for approximately 6 to 12 hours; its half-life is 5.6 to 14.8 hours. HCTZ is actively secreted into the proximal tubule by renal organic anion transporters and is eliminated through urine.<xref ref-type="bibr" rid="article-160212.r29">[29]</xref></p>
      </sec>
      <sec id="article-160212.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>The single-pill combination of angiotensin II receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) is available in oral tablet formulations.</p>
        <p>
<bold>Adult Dosage and <bold>Strengths</bold></bold>
</p>
        <p>
<bold>Valsartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>80 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>160 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>320 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>160 mg/25 mg</p>
          </list-item>
          <list-item>
            <p>320 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 160 mg/12.5 mg once daily</p>
        <p>Maximum dose: 320 mg/25 mg once daily</p>
        <p>The dose of the valsartan-HCTZ combination can be titrated 1 to 2 weeks after therapy is initiated, and maximum antihypertensive effects are achieved 2 to 4 weeks after&#x000a0;treatment initiation.</p>
        <p>
<bold>Olmesartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>20 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>40 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>40 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 20 mg/12.5 mg once daily</p>
        <p>Maximum dose: 40 mg/25 mg once daily</p>
        <p>The dose of olmesartan-HCTZ combination should be titrated every 2 to 4 weeks until blood pressure is controlled.</p>
        <p>
<bold>Telmisartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>40 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>80 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>80 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 40 mg/12.5 mg once daily</p>
        <p>Maximum dose: 160 mg/25 mg once daily</p>
        <p>The medication should be started at the lowest possible dose and titrated every 1 to 2 weeks according to the patient's blood pressure.</p>
        <p>
<bold>Irbesartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>150 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>300 mg/12.5 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 150 mg/12.5 mg once daily</p>
        <p>Maximum dose: 300 mg/25 mg once daily</p>
        <p>The dosage should be titrated every 1 to 2 weeks. The maximum antihypertensive effect is seen 3 to 4 weeks after treatment is initiated.</p>
        <p>
<bold>Candesartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>16 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>32 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>32 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 16 mg/12.5 mg once daily</p>
        <p>Maximum dose: 32 mg/25 mg once daily</p>
        <p>The maximal antihypertensive effect of candesartan and HCTZ is observed 4 weeks after initiating the medication. A patient with uncontrolled blood pressure on 25 mg of HCTZ would only benefit from the combination of 16 mg of candesartan and 12.5 mg of HCTZ. A patient who develops hypokalemia on 25 mg of HCTZ can expect potassium levels to improve after initiating a combination of candesartan and HCTZ.</p>
        <p>
<bold>Losartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>50 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>100 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>100 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose:&#x000a0;50 mg/12.5 mg</p>
        <p>Maximum dose: 100 mg/25 mg daily (ie, 100 mg/25 mg once daily or 50 mg/12.5 mg twice daily)</p>
        <p>The&#x000a0;typical starting dose of losartan and HCTZ is 50 mg/12.5 mg. If blood pressure remains uncontrolled after 3 weeks of therapy, the dose can be increased to 100/25 mg once daily.</p>
        <p>
<bold>Eprosartan and hydrochlorothiazide</bold>
</p>
        <p>Available doses:</p>
        <list list-type="bullet">
          <list-item>
            <p>600 mg/12.5 mg</p>
          </list-item>
          <list-item>
            <p>600 mg/25 mg</p>
          </list-item>
        </list>
        <p>Initial dose: 600 mg/12.5mg once daily</p>
        <p>Maximum dose: 600 mg/25 mg once daily</p>
        <p>The dose of eprosartan and HCTZ combination can be increased to a maximum of 600 mg/25 mg if blood pressure readings remain high 3 weeks after starting therapy.<xref ref-type="bibr" rid="article-160212.r22">[22]</xref><xref ref-type="bibr" rid="article-160212.r35">[35]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage changes are required for patients with mild and moderate renal impairment. However, combination ARB-HCTZ medications are&#x000a0;contraindicated for patients with end-stage renal disease, as hydrochlorothiazide can induce azotemia in patients with severe renal impairment.&#x000a0;According to KDIGO guidelines, hypertension is a significant risk factor for the development and progression of chronic kidney disease (CKD). A diagnosis of CKD is made for patients with an estimated glomerular filtration rate &#x0003c;60 mL/min/1.73 m<sup>2</sup> and a urinary albumin-to-creatinine ratio &#x02265;300 mg/g for 3 months or longer.&#x000a0;Among patients with type 1 or type 2 diabetes and CKD, treatment with an ACE inhibitor or ARB reduces the risk of progressing to end-stage renal disease (ESRD). Additionally, antihypertensive therapy mitigates the risk of cardiovascular events.<xref ref-type="bibr" rid="article-160212.r36">[36]</xref>&#x000a0;</p>
        <p><bold>Hepatic impairment:</bold> Minor electrolyte imbalances can precipitate hepatic encephalopathy&#x000a0;in patients with cirrhosis; electrolyte levels should be carefully monitored&#x000a0;in these patients.<xref ref-type="bibr" rid="article-160212.r37">[37]</xref>&#x000a0;Valsartan should be avoided for patients with marked hepatic dysfunction. However, if&#x000a0;valsartan must be&#x000a0;administered, the daily dose should not exceed 80 mg.<xref ref-type="bibr" rid="article-160212.r23">[23]</xref>&#x000a0;Losartan undergoes extensive first-pass metabolism in the liver mediated by the cytochrome P450 system; initial dosing should be half the standard in patients with severe hepatic impairment.<xref ref-type="bibr" rid="article-160212.r30">[30]</xref>&#x000a0;ARBs inhibit the renin-angiotensin-aldosterone system (RAAS), reducing vasoconstriction. Compensatory vasoconstriction is critical for maintaining blood pressure in patients with cirrhosis. The American Association for the Study of Liver Diseases (AASLD) guidelines recommend avoiding ARBs for patients with cirrhosis-related ascites due to potential adverse effects on systemic hemodynamics and renal function.<xref ref-type="bibr" rid="article-160212.r38">[38]</xref><xref ref-type="bibr" rid="article-160212.r39">[39]</xref>&#x000a0;Thiazide diuretics can cause hypovolemic hyperosmolar hyponatremia in patients with cirrhosis&#x000a0;and ascites, especially older patients. The concomitant use of aldosterone antagonists exacerbates this complication.<xref ref-type="bibr" rid="article-160212.r40">[40]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Medications that target the RAAS can result in fetal renal dysfunction, pulmonary hypoplasia, patent ductus arteriosus, hypocalvaria, and musculoskeletal deformities.&#x000a0;HCTZ crosses the placenta and has adverse effects on the fetus, such as hyperbilirubinemia, thrombocytopenia, and oligohydramnios.<xref ref-type="bibr" rid="article-160212.r41">[41]</xref> HCTZ also causes diuresis, which can potentially lead to hypoperfusion of the placenta and&#x000a0;subsequent intrauterine growth restriction and fetal distress.&#x000a0;According to AHA/ACC guidelines, women with hypertension who are pregnant or planning&#x000a0;to become pregnant should switch to methyldopa, nifedipine, or labetalol. Clinicians&#x000a0;are advised to avoid&#x000a0;prescribing ACE inhibitors, ARBs, or direct renin inhibitors to pregnant women.<xref ref-type="bibr" rid="article-160212.r8">[8]</xref>&#x000a0;According to&#x000a0;ISH&#x000a0;guidelines, renin-angiotensin system (RAS) blockers, including ACE inhibitors, ARBs, and direct renin inhibitors, are contraindicated for pregnant women due to adverse fetal and neonatal outcomes.<xref ref-type="bibr" rid="article-160212.r10">[10]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>HCTZ is secreted in human milk and&#x000a0;is associated with adverse neonatal effects. Women who are nursing must discontinue either the drug or breastfeeding. Intense diuresis induced by HCTZ can reduce breast milk production.&#x000a0;Neonates who ingest HCTZ&#x000a0;in breast milk&#x000a0;may experience acute renal injury, hypokalemia, hyperbilirubinemia, hyponatremia, and hypochloremia.&#x000a0;The latter effect&#x000a0;is associated with significant mortality among preterm neonates.<xref ref-type="bibr" rid="article-160212.r42">[42]</xref> Intensive diuresis using high doses of diuretics (eg, hydrochlorothiazide 100&#x02013;150 mg daily) has historically been&#x000a0;administered to suppress postpartum lactation. However, no instances of lactation suppression have been reported in patients administered the standard antihypertensive-hydrochlorothiazide doses (25 to 50 mg daily). There is limited information on the effect of ARBs on lactation. However, since all ARBs are highly bound to plasma proteins (&#x0003e;98%) and are poorly absorbed when administered orally, they are&#x000a0;thought to be unlikely to&#x000a0;affect nursing infants.<xref ref-type="bibr" rid="article-160212.r43">[43]</xref>&#x000a0;</p>
        <p><bold>Pediatric patients: </bold>The safety and efficacy of ARB/HCTZ single-pill combination products have not been established in the pediatric population.&#x000a0;However,&#x000a0;ARBs have been shown to lower&#x000a0;blood pressure&#x000a0;in&#x000a0;children aged 6 months to 6 years and have a favorable safety profile.<xref ref-type="bibr" rid="article-160212.r44">[44]</xref>&#x000a0;Neonates exposed to the ARB-HCTZ combination may require exchange transfusions and dialysis due to renal impairment. The safety of the ARB-HCTZ combination in&#x000a0;patients older than 28 days has not been established.&#x000a0;</p>
        <p><bold>Older patients:&#x000a0;</bold>No difference in safety, efficacy, or adverse effects profile&#x000a0;has been documented&#x000a0;in older adults. Diuretic agents may cause orthostatic hypotension in these patients; however, there is no evidence that ARB-HCTZ medications result in this condition in older patients.<xref ref-type="bibr" rid="article-160212.r45">[45]</xref></p>
      </sec>
      <sec id="article-160212.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The incidence and severity of adverse reactions were reported lower&#x000a0;for patients on ARB-HCTZ combination therapy than for patients&#x000a0;taking&#x000a0;individual drugs. The incidence of adverse reactions is independent of age, race, or sex. During clinical trials,&#x000a0;ARB-HCTZ was discontinued in 2.3% of patients due to adverse effects.</p>
        <p>Severe adverse effects&#x000a0;associated with&#x000a0;hydrochlorothiazide administration include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic lupus erythematosus (SLE) flares</p>
          </list-item>
          <list-item>
            <p>Hyperuricemia</p>
          </list-item>
          <list-item>
            <p>Worsening dyslipidemia</p>
          </list-item>
          <list-item>
            <p>Acute angle closure glaucoma</p>
          </list-item>
          <list-item>
            <p>Urea level elevations in&#x000a0;patients with renal dysfunction</p>
          </list-item>
          <list-item>
            <p>Electrolyte imbalances (eg, hypokalemia, hyponatremia, and hypercalcemia)</p>
          </list-item>
        </list>
        <p>Hydrochlorothiazide diuretics are also known to cause hyperglycemia, pancreatitis, hyperbilirubinemia, gastroenteritis, aplastic anemia, hemolytic anemia, pulmonary edema, bleeding dyscrasia, headache, vertigo, and blurred vision. The risk of squamous cell carcinoma (non-melanoma skin cancer) was found to be higher&#x000a0;for White patients&#x000a0;receiving&#x000a0;HCTZ&#x000a0;compared to&#x000a0;the general population.<xref ref-type="bibr" rid="article-160212.r30">[30]</xref><xref ref-type="bibr" rid="article-160212.r46">[46]</xref>&#x000a0;There is a significantly higher risk of drug-induced liver injury (DILI)&#x000a0;for patients receiving azilsartan compared&#x000a0;to valsartan.<xref ref-type="bibr" rid="article-160212.r47">[47]</xref></p>
        <p>The adverse effects associated with ARBs include dizziness, hyperkalemia, sinusitis, angioedema, cough, and enteropathy. The incidence and severity of hypotension&#x000a0;increase with the concurrent&#x000a0;administration of diuretics such as HCTZ. Providers should avoid prescribing candesartan to patients with hyperuricemia.<xref ref-type="bibr" rid="article-160212.r48">[48]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cough:</bold> ARBs increase bradykinin levels, which&#x000a0;stimulate&#x000a0;the production of prostaglandins that&#x000a0;cause bronchial irritation.</p>
          </list-item>
          <list-item>
            <p><bold>Hypotension:</bold> Hypotension is&#x000a0;observed more commonly&#x000a0;in patients receiving&#x000a0;telmisartan. The ONTARGET trial highlighted the impact of hypotension in these patients, leading to the discontinuation of this drug.<xref ref-type="bibr" rid="article-160212.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Enteropathy:</bold> The&#x000a0;administration&#x000a0;of olmesartan can&#x000a0;cause a sprue-like enteropathy.<xref ref-type="bibr" rid="article-160212.r50">[50]</xref>&#x000a0;Chronic diarrhea, weight loss, and villous atrophy have been documented. These patients&#x000a0;typically test negative for celiac disease, and the symptoms recur if olmesartan is restarted.</p>
          </list-item>
          <list-item>
            <p><bold>Hyperkalemia:</bold> Aldosterone is&#x000a0;a significant regulator of&#x000a0;potassium excretion. Since ARBs&#x000a0;prevent the effects of angiotensin and&#x000a0;aldosterone, patients receiving these medications are at an increased risk of hyperkalemia. This adverse effect is more common&#x000a0;in patients with chronic kidney disease&#x000a0;who are taking potassium-sparing diuretics such as aldactone. To a certain extent, the&#x000a0;hypokalemia induced by hydrochlorothiazide&#x000a0;is countered by&#x000a0;ARB-induced hyperkalemia.<xref ref-type="bibr" rid="article-160212.r51">[51]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Concurrent administration of ARB-HCTZ with alcohol, narcotics, and barbiturates can precipitate hypotension. Patients receiving ARB-HCTZ may develop increased responsiveness to lower doses of curare-derived muscle relaxants (eg, rocuronium). Medications that&#x000a0;reduce gastrointestinal motility (eg, opioids, atropine)&#x000a0;cause increased bioavailability of HCTZ. In contrast, prokinetic agents decrease the bioavailability of the drug combination. Fluconazole&#x000a0;inhibits the&#x000a0;activation of losartan into its active metabolite,&#x000a0;reducing its efficacy. Simultaneous&#x000a0;administration of HCTZ and antineoplastic agents can precipitate the latter's toxicity as their renal clearance is reduced.&#x000a0;Elevated serum lithium levels have been observed in patients who are&#x000a0;also receiving&#x000a0;ARB-HCTZ. Co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) can worsen renal function, especially&#x000a0;in older and dehydrated patients. When&#x000a0;administered simultaneously with drugs such as NSAIDs, ARB-HCTZ can reduce the renal clearance of digoxin, leading to toxicity.<xref ref-type="bibr" rid="article-160212.r7">[7]</xref>&#x000a0;According to the product labeling, thiazide diuretics can reduce calcium excretion. Hydrochlorothiazide&#x000a0;may also&#x000a0;cause&#x000a0;minor&#x000a0;elevations in blood calcium levels, even in healthy patients. Significant hypercalcemia is suggestive of&#x000a0;underlying hyperparathyroidism. Hydrochlorothiazide should be&#x000a0;discontinued before assessing parathyroid gland function.<xref ref-type="bibr" rid="article-160212.r52">[52]</xref><xref ref-type="bibr" rid="article-160212.r7">[7]</xref></p>
      </sec>
      <sec id="article-160212.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The combination of ARBs and HCTZ should not be&#x000a0;administered to patients with&#x000a0;the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypersensitivity to sulfonamide-derived drugs:</bold>&#x000a0;Individuals with a history of hypersensitivity to any component of the ARB-HCTZ combination, angioedema, or anaphylaxis should not take this medication.&#x000a0;These conditions are absolute contraindications to the ARB-HCTZ combination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy:</bold> Both ARBs and HCTZ&#x000a0;are known to have teratogenic effects on the developing fetus. Therefore, if a woman becomes pregnant while taking this combination medication, it&#x000a0;must be discontinued immediately.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Receiving aliskiren:</bold> The simultaneous&#x000a0;administration of aliskiren&#x000a0;and&#x000a0;ARB-HCTZ significantly increases the risk of hypotension and hyperkalemia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Bilateral renal artery stenosis and heart failure with hypotension:</bold> Patients with conditions such as bilateral renal artery stenosis and heart failure accompanied by hypotension rely heavily on the RAAS to regulate blood pressure and should not be administered ARBs. In patients with this or similar conditions, ARBs may precipitate renal failure and hyperkalemia.<xref ref-type="bibr" rid="article-160212.r48">[48]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fetal toxicity:</bold>&#x000a0;Upon detection of pregnancy, discontinue single pill combinations of ARB-HCTZ promptly. Agents affecting the renin-angiotensin system can result in fetal injury and mortality.<xref ref-type="bibr" rid="article-160212.r53">[53]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Healthcare providers should remain informed about&#x000a0;industry&#x000a0;recalls of ARBs, including the past recalls of valsartan, irbesartan, and losartan, due to the presence of contaminants such as NMBA and NDMA.&#x000a0;Providers should be aware of the specific batches affected and updates from regulatory agencies like the FDA regarding any new recalls related to these contaminants due to their carcinogenic potential.<xref ref-type="bibr" rid="article-160212.r54">[54]</xref></p>
          </list-item>
          <list-item>
            <p>Hydrochlorothiazide&#x000a0;administration&#x000a0;in kidney transplant recipients&#x000a0;is associated with an increased incidence of basal cell carcinoma. This&#x000a0;relationship underscores the importance of frequent dermatological monitoring, particularly for patients continuously exposed to sunlight or other ultraviolet sources.<xref ref-type="bibr" rid="article-160212.r55">[55]</xref>&#x000a0;Despite previous pharmacovigilance reports suggesting a link, a randomized, placebo-controlled trial&#x000a0;involving 30 healthy volunteers found that HCTZ 25 mg daily for 15 days did not increase photosensitivity to UVA or UVB radiation or cause phototoxic or carcinogenic effects. In vitro studies with human keratinocytes also found no&#x000a0;adverse effects related to phototoxicity or carcinogenesis due to&#x000a0;HCTZ administration combined with UVB exposure.<xref ref-type="bibr" rid="article-160212.r56">[56]</xref>&#x000a0;A systematic review and meta-analysis on antihypertensive drugs&#x000a0;concluded that diuretics (especially hydrochlorothiazide)&#x000a0;are associated with an increased risk of non-melanoma skin cancer (NMSC). However, this risk was predominantly observed during studies that did not adjust for sun exposure or smoking. Cohort studies and studies that corrected these factors did not find a significantly increased risk of NMSC. Furthermore, significant publication bias was identified in some studies. In conclusion, while observational data suggest a link between HCTZ and skin cancer, the evidence from well-controlled studies correcting for confounding factors is less conclusive. Further research and ongoing surveillance is required.<xref ref-type="bibr" rid="article-160212.r57">[57]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-160212.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Serum potassium levels should be monitored&#x000a0;in patients with chronic kidney disease&#x000a0;who are prescribed ARB-HCTZ. Among the patients who do not have renal dysfunction, potassium is not regularly monitored, as the incidence of new-onset hyperkalemia after ARB administration is 2% and&#x000a0;typically rises only&#x000a0;0.2 mmol/L.<xref ref-type="bibr" rid="article-160212.r58">[58]</xref>&#x000a0;Hydrochlorothiazide&#x000a0;increases potassium&#x000a0;excretion and&#x000a0;may cause hypokalemia; the hyperkalemia caused by ARBs is balanced by&#x000a0;HCTZ-induced&#x000a0;hypokalemia.<xref ref-type="bibr" rid="article-160212.r59">[59]</xref>&#x000a0;For patients receiving ARB therapy, renal parameters should be monitored routinely. Clinicians should monitor serum glucose levels in patients with diabetes mellitus and prediabetes, as HCTZ can cause hyperglycemia.<xref ref-type="bibr" rid="article-160212.r17">[17]</xref>&#x000a0;Patients with a past or family history of hyperuricemia should be monitored for features of an acute flare of gout, as HCTZ causes increased uric acid reabsorption.<xref ref-type="bibr" rid="article-160212.r60">[60]</xref>&#x000a0;According to ADA&#x000a0;guidelines, serum creatinine elevations (up to 30%&#x000a0;above baseline) with ARBs should not be mistaken for acute kidney injury (AKI). Therefore, ARBs should not be discontinued for these minor increases in serum creatinine unless accompanied by volume depletion.<xref ref-type="bibr" rid="article-160212.r16">[16]</xref>&#x000a0;According to ESC guidelines, regular patient follow-up is essential during hypertension therapy, as it allows for assessing blood pressure control, evaluating the need for lifestyle and pharmacological treatments, identifying hypertensive-mediated organ damage (HMOD), ascertaining necessary modifications to risk factors, and verifying medication adherence.<xref ref-type="bibr" rid="article-160212.r61">[61]</xref></p>
      </sec>
      <sec id="article-160212.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The median lethal dose (LD<sub>50</sub>) of each drug combination depends on the constituent ARB. The literature does not provide toxicity data for each ARB and HCTZ combination.&#x000a0;</p>
        <p>An overdose of ARB can cause hypotension, tachycardia, or bradycardia. The LD<sub>50</sub>&#x000a0;for each ARB is listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Valsartan: &#x0003e;2 g/kg</p>
          </list-item>
          <list-item>
            <p>Olmesartan: &#x0003e;1.5 g/kg</p>
          </list-item>
          <list-item>
            <p>Telmisartan: &#x0003e;150 mg/kg</p>
          </list-item>
          <list-item>
            <p>Irbesartan: &#x0003e;2000 mg/kg</p>
          </list-item>
          <list-item>
            <p>Losartan: &#x0003e;2000 mg/kg</p>
          </list-item>
        </list>
        <p>According to animal studies, the LD<sub>50</sub>&#x000a0;of HCTZ is &#x0003e;10 g/kg.&#x000a0;Hydrochlorothiazide toxicity can cause excessive diuresis, leading to hypotension and electrolyte imbalance.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The management of an ARB-HCTZ overdose involves supportive care with intravenous fluids and ensuring electrolyte balance. Terlipressin can be used to treat the patient if the hypotension is not responsive to vasopressors.<xref ref-type="bibr" rid="article-160212.r62">[62]</xref></p>
      </sec>
      <sec id="article-160212.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Adequate&#x000a0;management of hypertension is crucial&#x000a0;for reducing cardiovascular mortality, as it is one of the major risk factors for cardiovascular diseases. Inadequate control of blood pressure poses a significant public health concern. However, patients can achieve&#x000a0;appropriate blood pressure targets through combination therapy, such as the angiotensin receptor blocker-hydrochlorothiazide single-pill combination. This therapy improves blood pressure control and metabolic parameters&#x000a0;while reducing other cardiovascular risk factors. Hydrochlorothiazide is available with various angiotensin receptor blockers, including telmisartan, valsartan, olmesartan, candesartan, and losartan. However, caution should be exercised when prescribing the angiotensin receptor blocker and hydrochlorothiazide combination to patients with renal impairments and electrolyte imbalances. Clinicians must&#x000a0;rule out absolute contraindications, such as pregnancy, bilateral renal artery stenosis, and concurrent use of aliskiren, before initiating this medication.</p>
        <p>Each healthcare provider should have a clearly defined role in optimizing treatment outcomes. Effective communication among the healthcare team members is crucial to ensuring appropriate patient care. During one prospective study, pharmacist-managed hypertension care in collaboration with physicians led to an average&#x000a0;systolic blood pressure (SBP) reduction of 10.83 mm Hg. A&#x000a0;greater proportion of patients in the pharmacist-managed group achieved their blood pressure goal (&#x0003c;130/80 mm Hg) compared to those managed solely by physicians (56.5% vs. 20.8%, P = 0.012). These findings underscore the&#x000a0;benefit of pharmacist involvement in improving hypertension management outcomes in ambulatory care settings.<xref ref-type="bibr" rid="article-160212.r63">[63]</xref>&#x000a0;Evidence-based&#x000a0;practice should guide the selection of antihypertensive therapy, and healthcare providers should thoroughly explain the potential adverse effects and benefits of the angiotensin receptor blocker and hydrochlorothiazide combination to the patient and&#x000a0;any caregivers. By promoting coordination and communication among healthcare team members, errors&#x000a0;are minimized, and patient outcomes are improved. Cardiologists and nephrologists should be consulted&#x000a0;regarding secondary causes of hypertension and end-organ damage. Emergency medicine physicians should be consulted for rapid stabilization&#x000a0;of patients who have overdosed.&#x000a0;An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, and nurses significantly&#x000a0;reduces potential adverse effects, improves the disease course, and improves patient outcomes&#x000a0;related&#x000a0;to angiotensin receptor blocker and hydrochlorothiazide therapy.</p>
      </sec>
      <sec id="article-160212.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=160212&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=160212">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/160212/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=160212">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-160212.s10">
        <title>References</title>
        <ref id="article-160212.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostchega</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fryar</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Nwankwo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018.</article-title>
            <source>NCHS Data Brief</source>
            <year>2020</year>
            <month>Apr</month>
            <issue>364</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">32487290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bragazzi</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Younis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>1223</fpage>
            <page-range>1223-1233</page-range>
            <pub-id pub-id-type="pmid">33583201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirabito Colafella</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bov&#x000e9;e</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Danser</surname>
                <given-names>AHJ</given-names>
              </name>
            </person-group>
            <article-title>The renin-angiotensin-aldosterone system and its therapeutic targets.</article-title>
            <source>Exp Eye Res</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>186</volume>
            <fpage>107680</fpage>
            <pub-id pub-id-type="pmid">31129252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Presta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Figliuzzi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Citoni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Battistoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.</article-title>
            <source>High Blood Press Cardiovasc Prev</source>
            <year>2021</year>
            <month>May</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-262</page-range>
            <pub-id pub-id-type="pmid">33710599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study.</article-title>
            <source>Health Sci Rep</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e1056</fpage>
            <pub-id pub-id-type="pmid">36741853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendorff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Findeiss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <collab>American Heart Association, American College of Cardiology, and American Society of Hypertension</collab>
            </person-group>
            <article-title>Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.</article-title>
            <source>J Am Soc Hypertens</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>453</fpage>
            <page-range>453-98</page-range>
            <pub-id pub-id-type="pmid">25840695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teles</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pe&#x000e7;anha de Miranda Coelho</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Albino</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ver&#x000e7;osa Pacheco</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Rodrigues de Oliveira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>MAD</given-names>
              </name>
              <name>
                <surname>Di&#x000f3;genes M Feitosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bezerra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2163903</fpage>
            <pub-id pub-id-type="pmid">36637019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Derington</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Herrick</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zheutlin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Conroy</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Bress</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial.</article-title>
            <source>Hypertension</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>80</volume>
            <issue>8</issue>
            <fpage>1749</fpage>
            <page-range>1749-1758</page-range>
            <pub-id pub-id-type="pmid">37288570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brunstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Januszewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muiesan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agabiti-Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Algharably</surname>
                <given-names>EAE</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benetos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hitij</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cifkova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cornelissen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Danser</surname>
                <given-names>AHJ</given-names>
              </name>
              <name>
                <surname>Pinho</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Delles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Dorobantu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doumas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Alfonso</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Halimi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>J&#x000e1;rai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jelakovi&#x00107;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuznetsova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lurbe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miglinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narkiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niiranen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palatini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Persu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polonia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sarafidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spronck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stabouli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Taddei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomopoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van de Borne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).</article-title>
            <source>J Hypertens</source>
            <year>2023</year>
            <month>Dec</month>
            <day>01</day>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>1874</fpage>
            <page-range>1874-2071</page-range>
            <pub-id pub-id-type="pmid">37345492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suchard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Schuemie</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Madigan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hripcsak</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>591</fpage>
            <page-range>591-603</page-range>
            <pub-id pub-id-type="pmid">34304580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Lyle</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kizer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>H&#x000f8;ieggen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Os</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2007</year>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-305</page-range>
            <pub-id pub-id-type="pmid">17703637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Slater</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smithgall</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension.</article-title>
            <source>Ann Pharmacother</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>11</issue>
            <fpage>1143</fpage>
            <page-range>1143-1151</page-range>
            <pub-id pub-id-type="pmid">29808707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association Professional Practice Committee</collab>
            <article-title>11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>45</volume>
            <issue>Suppl 1</issue>
            <fpage>S175</fpage>
            <page-range>S175-S184</page-range>
            <pub-id pub-id-type="pmid">34964873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>342</fpage>
            <page-range>342-51</page-range>
            <pub-id pub-id-type="pmid">26395424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Angiotensin II Receptor Antagonists</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foulquier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Namsolleck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Recarti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steckelings</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.</article-title>
            <source>Drugs</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">26631237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almutlaq</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alamro</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alroqi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barhoumi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Classical and Counter-Regulatory Renin-Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology.</article-title>
            <source>CJC Open</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>1060</fpage>
            <page-range>1060-1074</page-range>
            <pub-id pub-id-type="pmid">33875979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fravel</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide.</article-title>
            <source>Am J Hypertens</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>573</fpage>
            <page-range>573-586</page-range>
            <pub-id pub-id-type="pmid">35404993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis.</article-title>
            <source>Int J Hypertens</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>6670183</fpage>
            <pub-id pub-id-type="pmid">33996152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Th&#x000fc;rmann</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Valsartan: a novel angiotensin type 1 receptor antagonist.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>337</fpage>
            <page-range>337-50</page-range>
            <pub-id pub-id-type="pmid">11249553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunner</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.</article-title>
            <source>J Hum Hypertens</source>
            <year>2002</year>
            <month>May</month>
            <volume>16 Suppl 2</volume>
            <fpage>S13</fpage>
            <page-range>S13-6</page-range>
            <pub-id pub-id-type="pmid">11967728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gleiter</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>M&#x000f6;rike</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of candesartan.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2002</year>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-17</page-range>
            <pub-id pub-id-type="pmid">11825094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gehr</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of losartan.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2005</year>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>797</fpage>
            <page-range>797-814</page-range>
            <pub-id pub-id-type="pmid">16029066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castilla-Ojo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turkson-Ocran</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Conlin</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Juraschek</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>10</issue>
            <fpage>915</fpage>
            <page-range>915-922</page-range>
            <pub-id pub-id-type="pmid">37695134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balakumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bishnoi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Mahadevan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Telmisartan in the management of diabetic nephropathy: a contemporary view.</article-title>
            <source>Curr Diabetes Rev</source>
            <year>2012</year>
            <month>May</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-90</page-range>
            <pub-id pub-id-type="pmid">22429010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Commander</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Boakye-Agyeman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Melloni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hornik</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al-Uzri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mendley</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee</collab>
            </person-group>
            <article-title>Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>368</fpage>
            <page-range>368-377</page-range>
            <pub-id pub-id-type="pmid">33029806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.</article-title>
            <source>Drug Saf</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-54</page-range>
            <pub-id pub-id-type="pmid">25416320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunner</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Olmesartan medoxomil: current status of its use in monotherapy.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2006</year>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-40</page-range>
            <pub-id pub-id-type="pmid">17323586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zoppi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A drug safety evaluation of valsartan.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>295</fpage>
            <page-range>295-303</page-range>
            <pub-id pub-id-type="pmid">21142805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gurrieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Glazer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of multiple doses of valsartan in patients with heart failure.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>801</fpage>
            <page-range>801-7</page-range>
            <pub-id pub-id-type="pmid">12409989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stangier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.</article-title>
            <source>J Int Med Res</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>149</fpage>
            <page-range>149-67</page-range>
            <pub-id pub-id-type="pmid">11014323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;nner</surname>
                <given-names>G</given-names>
              </name>
              <collab>Multicentre Study Group</collab>
            </person-group>
            <article-title>Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.</article-title>
            <source>Blood Press Suppl</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>2</volume>
            <fpage>22</fpage>
            <page-range>22-30</page-range>
            <pub-id pub-id-type="pmid">19203019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group</collab>
            <article-title>KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.</article-title>
            <source>Kidney Int</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>5S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S127</page-range>
            <pub-id pub-id-type="pmid">36272764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000e9;zsi</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>255</fpage>
            <page-range>255-266</page-range>
            <pub-id pub-id-type="pmid">26940560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Runyon</surname>
                <given-names>BA</given-names>
              </name>
              <collab>AASLD</collab>
            </person-group>
            <article-title>Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.</article-title>
            <source>Hepatology</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>1651</fpage>
            <page-range>1651-3</page-range>
            <pub-id pub-id-type="pmid">23463403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhence</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dodge</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>315</fpage>
            <page-range>315-323.e17</page-range>
            <pub-id pub-id-type="pmid">37495200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garbuzenko</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Arefyev</surname>
                <given-names>NO</given-names>
              </name>
            </person-group>
            <article-title>Current approaches to the management of patients with cirrhotic ascites.</article-title>
            <source>World J Gastroenterol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>28</day>
            <volume>25</volume>
            <issue>28</issue>
            <fpage>3738</fpage>
            <page-range>3738-3752</page-range>
            <pub-id pub-id-type="pmid">31391769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoeltzenbein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tissen-Diabat&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fietz</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Zinke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kayser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weber-Schoendorfer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study.</article-title>
            <source>Clin Res Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>107</volume>
            <issue>8</issue>
            <fpage>679</fpage>
            <page-range>679-687</page-range>
            <pub-id pub-id-type="pmid">29574489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalikkot Thekkeveedu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramarao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dankhara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alur</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hypochloremia Secondary to Diuretics in Preterm Infants: Should Clinicians Pay Close Attention?</article-title>
            <source>Glob Pediatr Health</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>2333794X21991014</fpage>
            <pub-id pub-id-type="pmid">33614850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Treating Hypertension During Breastfeeding.</article-title>
            <source>Breastfeed Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-96</page-range>
            <pub-id pub-id-type="pmid">29369692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webb</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Shahinfar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Massaad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dankner</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McCrary Sisk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blaustein</surname>
                <given-names>RO</given-names>
              </name>
            </person-group>
            <article-title>A randomized, open-label, dose-response study of losartan in hypertensive children.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>07</day>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>1441</fpage>
            <page-range>1441-8</page-range>
            <pub-id pub-id-type="pmid">24875194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Neldam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>380</fpage>
            <page-range>380-8</page-range>
            <pub-id pub-id-type="pmid">23730986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hundemer</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Petrcich</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Canney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bugeja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>e2123365</fpage>
            <pub-id pub-id-type="pmid">34524440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.</article-title>
            <source>Drug Saf</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>673</fpage>
            <page-range>673-686</page-range>
            <pub-id pub-id-type="pmid">38512445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r48">
          <label>48</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hill</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <chapter-title>Angiotensin II Receptor Blockers (ARB)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30725712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlaimont</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Billiouw</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brohet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Gazagnes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krzesinski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Missault</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Persu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pi&#x000e9;rard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rottiers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vanhooren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Van Mieghem</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vervaet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Lessons from ONTARGET.</article-title>
            <source>Acta Clin Belg</source>
            <year>2008</year>
            <season>May-Jun</season>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>142</fpage>
            <page-range>142-51</page-range>
            <pub-id pub-id-type="pmid">18714845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bashari</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity.</article-title>
            <source>Gastroenterology Res</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>150</fpage>
            <page-range>150-154</page-range>
            <pub-id pub-id-type="pmid">32864026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Momoniat</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ilyas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors and ARBs: Managing potassium and renal function.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>86</volume>
            <issue>9</issue>
            <fpage>601</fpage>
            <page-range>601-607</page-range>
            <pub-id pub-id-type="pmid">31498767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griebeler</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thapa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hathcock</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wermers</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>1166</fpage>
            <page-range>1166-73</page-range>
            <pub-id pub-id-type="pmid">26751196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buawangpong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teekachunhatean</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koonrungsesomboon</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e00644</fpage>
            <pub-id pub-id-type="pmid">32815286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butulija</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kadiyala</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>579</fpage>
            <page-range>579-584</page-range>
            <pub-id pub-id-type="pmid">32318933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahamimov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Telem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davidovichi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bielopolski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinmetz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nesher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lichtenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rozen-Zvi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The association between hydrochlorothiazide use and non-melanoma skin cancer in kidney transplant recipients.</article-title>
            <source>Clin Kidney J</source>
            <year>2024</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>sfae126</fpage>
            <pub-id pub-id-type="pmid">38812910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;tzinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lauder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Millenaar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ukena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lerche</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Philipsen</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Reichrath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A randomized, placebo-controlled, trial to assess the photosensitizing, phototoxic and carcinogenic potential of hydrochlorothiazide in healthy volunteers.</article-title>
            <source>J Hypertens</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1853</fpage>
            <page-range>1853-1862</page-range>
            <pub-id pub-id-type="pmid">37702559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heisel</surname>
                <given-names>AGU</given-names>
              </name>
              <name>
                <surname>Vuurboom</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Daams</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>de Rie</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van den Born</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Olde Engberink</surname>
                <given-names>RHG</given-names>
              </name>
            </person-group>
            <article-title>The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis.</article-title>
            <source>Vascul Pharmacol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>150</volume>
            <fpage>107173</fpage>
            <pub-id pub-id-type="pmid">37084802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit.</article-title>
            <source>Circulation</source>
            <year>2008</year>
            <month>Oct</month>
            <day>14</day>
            <volume>118</volume>
            <issue>16</issue>
            <fpage>1609</fpage>
            <page-range>1609-11</page-range>
            <pub-id pub-id-type="pmid">18852376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Metabolic complications associated with use of diuretics.</article-title>
            <source>Semin Nephrol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-52</page-range>
            <pub-id pub-id-type="pmid">22099511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Jan</month>
            <day>12</day>
            <volume>344</volume>
            <fpage>d8190</fpage>
            <pub-id pub-id-type="pmid">22240117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brunstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Januszewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muiesan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Pinho</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Albini</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Doumas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nemcsik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodilla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agabiti-Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Algharably</surname>
                <given-names>EAE</given-names>
              </name>
              <name>
                <surname>Agnelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Benetos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hitij</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cornelissen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Danser</surname>
                <given-names>AHJ</given-names>
              </name>
              <name>
                <surname>Delles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huelgas</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>J&#x000e1;rai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Palatini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Persu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polonia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sarafidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thomopoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension.</article-title>
            <source>Eur J Intern Med</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>126</volume>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">38914505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Destro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cagnoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dognini</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Galimberti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Taietti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cavalleri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Telmisartan: just an antihypertensive agent? A literature review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>17</issue>
            <fpage>2719</fpage>
            <page-range>2719-35</page-range>
            <pub-id pub-id-type="pmid">22077832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160212.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chonko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Axtell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mayzel</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist Hypertension Management Quality Review at an Ambulatory Care Clinic.</article-title>
            <source>J Pharm Technol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-38</page-range>
            <pub-id pub-id-type="pmid">35141725</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
